Obesity Doc GLP-1 Concerns, 340B Abuse Raises Costs, & RPM Fraud Is Investigated

Hey all,

Happy hump day! Dr. McGowan's op-ed resonated with my GLP-1 journey. When United Health halted my Tirzepatide coverage, even though I have I qualify with T2 diabetes alongside my T1, I experienced dysmorphia and depression as my body changed. Resuming with cash-pay Mounjaro helped me recover. Enjoy the rundown.

Jacob Brody (Co-Founder & CEO, ZorroRX)

(Doximity Op-Med) Why One Doctor No Longer Believes GLP-1s Are the Answer

Dr. Christopher McGowan, a once-enthusiastic advocate for GLP-1 drugs like semaglutide and tirzepatide, now voices concern over their real-world use, citing high discontinuation rates and rapid weight regain after stopping the medications. He warns that relying on these drugs without long-term planning may lead to harmful cycles of weight loss and regain, muscle loss, psychological distress, and unsustainable costs. While for many patients GLP-1s are a life saver, the long term effects are only now being understood. Full Article.

(Health Capital Group) New Study Claims 340B Costs Employers $36 Billion in Inflated Hospital Bills

Although the 340B program remains a critical support for safety-net providers, new research underscores how larger hospital systems are exploiting it—reaping profits without delivering proportional charity care—prompting policymakers to consider reforms. A Health Capital Group study highlights how these large 340B hospitals drive up costs for employers by 7.5%, adding $36 billion annually to the commercial market, largely through higher outpatient prices and market consolidation. These findings intensify calls for greater transparency and accountability to ensure 340B fulfills its original mission. Full Article 

(Fierce Healthcare) Increased Audits Set New Bar for Remote Monitoring

Rising federal and internal audits of remote patient monitoring (RPM) companies are reshaping the digital health landscape by setting higher standards for compliance and documentation. As scrutiny intensifies—driven by concerns over billing accuracy and fraud—RPM providers are being pushed to improve transparency, accuracy, and integration with clinical workflows, signaling a maturing market that demands operational rigor. These developments mark a shift from rapid adoption to sustainable, accountable growth in digital health. Full Article